G1 Therapeutics, Inc. (NASDAQ:GTHX) to Post Q2 2024 Earnings of ($0.18) Per Share, HC Wainwright Forecasts

G1 Therapeutics, Inc. (NASDAQ:GTHX) – HC Wainwright upped their Q2 2024 EPS estimates for G1 Therapeutics in a research note issued on Thursday, May 2nd. HC Wainwright analyst E. White now forecasts that the company will post earnings per share of ($0.18) for the quarter, up from their previous estimate of ($0.19). HC Wainwright currently has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for G1 Therapeutics’ current full-year earnings is ($0.59) per share. HC Wainwright also issued estimates for G1 Therapeutics’ Q3 2024 earnings at ($0.17) EPS, Q4 2024 earnings at ($0.05) EPS, FY2024 earnings at ($0.61) EPS and FY2025 earnings at ($0.20) EPS.

G1 Therapeutics (NASDAQ:GTHX) last announced its quarterly earnings results on Wednesday, May 1st. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The business had revenue of $14.48 million during the quarter, compared to the consensus estimate of $15.21 million. G1 Therapeutics had a negative net margin of 36.40% and a negative return on equity of 74.75%. During the same period last year, the firm earned ($0.53) EPS.

GTHX has been the topic of a number of other reports. Wedbush reiterated an “outperform” rating and issued a $5.00 price target (up from $4.00) on shares of G1 Therapeutics in a research report on Wednesday, February 28th. Needham & Company LLC restated a “buy” rating and issued a $12.00 target price on shares of G1 Therapeutics in a research note on Wednesday, May 1st.

G1 Therapeutics Trading Down 0.5 %

GTHX stock opened at $4.25 on Monday. The company has a current ratio of 2.94, a quick ratio of 2.55 and a debt-to-equity ratio of 1.34. The firm has a market cap of $222.19 million, a P/E ratio of -6.85 and a beta of 1.71. G1 Therapeutics has a 1-year low of $1.08 and a 1-year high of $5.00. The business’s 50 day moving average is $4.02 and its 200-day moving average is $3.15.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Creative Financial Designs Inc. ADV increased its position in G1 Therapeutics by 98.1% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 35,280 shares of the company’s stock valued at $108,000 after acquiring an additional 17,475 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of G1 Therapeutics by 68.3% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 204,200 shares of the company’s stock valued at $294,000 after purchasing an additional 82,879 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in shares of G1 Therapeutics in the third quarter valued at approximately $189,000. abrdn plc bought a new position in G1 Therapeutics in the 4th quarter worth approximately $1,293,000. Finally, Choreo LLC acquired a new position in G1 Therapeutics during the 4th quarter worth $107,000. Institutional investors and hedge funds own 24.21% of the company’s stock.

Insider Transactions at G1 Therapeutics

In other news, insider Rajesh Malik sold 28,600 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $4.62, for a total transaction of $132,132.00. Following the sale, the insider now owns 169,938 shares in the company, valued at $785,113.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 8.23% of the stock is owned by company insiders.

About G1 Therapeutics

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.